CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 16 enrolled
Drug / intervention
Polymyxin -B fiber hemoperfusion systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00490477
NCT00490477Phase 3Completed
CompareCT.gov

Polymyxin-B Hemoperfusion Inactivates Circulating Proapoptotic Factors

University of Turin, Italy·interventional·Posted Jun 22, 2007·Updated Jun 8, 2010

In Brief

A Phase 3 clinical trial evaluating Polymyxin -B fiber hemoperfusion system for Gram-Negative Bacterial Infections and Sepsis. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGram-Negative Bacterial Infections, Sepsis
CountriesItaly
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 22, 2007
Enrollment StartMay 1, 2006
Primary CompletionJul 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.0 years ago

Interventions

Polymyxin -B fiber hemoperfusion systemdevice

two hours treatment for two days